Acasti Pharma Inc. (ACST)
After hours:
| Previous Close | 1.2800 |
| Open | 1.2800 |
| Bid | 1.1800 x 1200 |
| Ask | 1.2200 x 1200 |
| Day's Range | 1.1700 - 1.2990 |
| 52 Week Range | 1.0400 - 9.7600 |
| Volume | |
| Avg. Volume | 1,604,354 |
| Market Cap | 53.871M |
| Beta (5Y Monthly) | 1.42 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4640 |
| Earnings Date | Feb. 07, 2022 - Feb. 11, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.99 |
- GlobeNewswire
Acasti Pharma to Present at the H.C. Wainwright BioConnect 2022 Conference
LAVAL, Québec, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced that Jan D’Alvise, President and CEO of Acasti, will be presenting at the H.C. Wainwright BioConnect 2022 Conference being held virtually January 10-13, 2022. Acasti’s presentation will be available on-demand to registered attendees via the conference platform beginning Monday, January 10, 2022 at 7:00 AM Eastern Time. The webcast of the Company’s presen
- Simply Wall St.
Market Sentiment Around Loss-Making Acasti Pharma Inc. (CVE:ACST)
With the business potentially at an important milestone, we thought we'd take a closer look at Acasti Pharma Inc.'s...
- GlobeNewswire
Acasti Pharma Announces Interim Data Meets All Primary Endpoints for Pivotal PK Study for GTX-104
Bioavailability of GTX-104 compares favorably with the oral formulation of nimodipine; full PK study expected to report out as planned in H1’22LAVAL, Québec, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced positive results for GTX-104 based on its interim analysis of the first 20 of 50 normal healthy subjects in its pivotal pharmacokinetic (PK) bridging study. GTX-104 met both primary endpoints for Maximum Concentra
